There's new evidence suggesting the drug will find another large market.Novo Nordisk's (NVO 0.65%) type 2 diabetes drug Ozempic is a sensation, and it's no surprise why. In the first quarter, revenue from Ozempic rose 35% year over year to reach roughly $4.3 billion, and there's no sign of a slowdown in sight.In fact, it's very possible that sales of the medicine in its various formulations will continue to accelerate for far longer than investors suspect. So here are three new reasons why it's worth being ...